IndicationsStatusPurposePhase
RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02818023Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma
NCT02721459XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma